GHRL and pituitary gland adenoma: In accordance, we also found that treatment with mouse In2-ghrelin peptide increased cell viability in AtT-20 cell line which further supports the influence of this novel variant of the GHRL in the control of clinically relevant endpoints (i.e. cell viability and hormonal release) in pituitary adenomas of different species.